EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieQualitative StudieOpen Access · CC BY 4.0

PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy

Angelica Lindén Hirschberg, Antonia Morga, Franck Bruon, Karla Martins, Arianne Schild, Emily Hawryluk, Keena Roberts, Betsy Williams, Rossella E Nappi

Maturitas · 2025

DOI: 10.1016/j.maturitas.2025.108670 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Maturitas, 2025. Verfasst von Angelica Lindén Hirschberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Department of Gynecology and Reproductive Medicine, Karolinska…. Hauptthemen laut MEDLINE: Hot Flashes, Menopause, Vasomotor System. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc, Astellas Pharma Global Development, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: PERCEIVE collected insights from individuals for whom menopausal hormone therapy was unsuitable for addressing the effects and management of menopausal vasomotor symptoms. STUDY DESIGN: Interviews were conducted with participants exiting DAYLIGHT (NCT05033886), a phase 3b trial of fezolinetant. DAYLIGHT enrolled menopausal women aged 40-65 years who sought relief from moderate to severe vasomotor symptoms but had contraindications/precautions to, prior discontinuation of, or aversion to using hormone therapy. MAIN OUTCOME MEASURES: Menopausal symptoms, impacts of vasomotor symptoms, treatment use and satisfaction, and treatment barriers. RESULTS: Thirty-two participants were interviewed (mean age 57 years; mean age at onset of vasomotor symptoms 48 years; 78 % employed). Common symptoms were hot flashes (100 %), perspiration (81 %), and night sweats (44 %). Impacts of vasomotor symptoms included difficulty sleeping (94 %), tiredness from sleep interruptions (75 %), work impairment (75 %), emotionality (56 %), need to change clothes (56 %), and poor sleep quality (53 %). A quarter had never had their vasomotor symptoms treated; others had tried natural remedies (53 %), hormone therapy (31 %), acupuncture (9 %), over-the-counter agents (9 %), antidepressants (6 %), vaginal ring (3 %), and psychological therapy (3 %). Hormone therapy had the highest satisfaction rating (mean 3.7 on a 5-point scale); participants were slightly dissatisfied with natural remedies and antidepressants (mean 2.0 each). Treatment barriers included ineligibility and side effects (hormone therapy), ineffectiveness and limited access (nonhormonal agents), cost, menopause stigma, and lack of support from healthcare providers. CONCLUSIONS: Vasomotor symptoms associated with menopause negatively impacted daily life, particularly sleep, among participants unsuited to hormone therapy. Many sought nonhormonal treatments but found them ineffective, costly, and unsatisfactory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hot FlashesMenopauseVasomotor SystemAdultAgedFemaleHumansMiddle AgedFatigueInterviews as TopicPatient SatisfactionQualitative ResearchRetrospective StudiesSweating

Stichwörter der Autor:innen

Hot flashesMenopausePatient satisfactionQualitative researchSleepVasomotor symptoms

Autor:innen und Institutionen

  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden. Electronic address: angelica.…
  • Astellas Pharma Europe Ltd, Addlestone, UK. Electronic address: antonia_morga@astellas.com.
  • Astellas Pharma Europe Ltd, Levallois-Perret, France. Electronic address: franck.bruon@astellas.com.
  • Astellas Pharma Europe Ltd, Addlestone, UK. Electronic address: karla.martins@astellas.com.
  • Astellas Pharma Inc., Northbrook, IL, USA. Electronic address: arianne.schild@astellas.com.
  • IQVIA Inc., New York, NY, USA. Electronic address: emily.hawryluk@iqvia.com.

Förderung

  • Astellas Pharma Inc
  • Astellas Pharma Global Development
  • Astellas Pharma

Zitieren

APA

Hirschberg, A. L., Morga, A., Bruon, F., Martins, K., Schild, A., Hawryluk, E., Roberts, K., Williams, B., & Nappi, R. E. (2025). PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy. Maturitas. https://doi.org/10.1016/j.maturitas.2025.108670

Vancouver

Hirschberg AL, Morga A, Bruon F, Martins K, Schild A, Hawryluk E, et al. PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy. Maturitas. 2025. doi:10.1016/j.maturitas.2025.108670

BibTeX
@article{Hirschberg2025,
  author = {Hirschberg, Angelica Lindén and Morga, Antonia and Bruon, Franck and Martins, Karla and Schild, Arianne and Hawryluk, Emily and Roberts, Keena and Williams, Betsy and Nappi, Rossella E},
  title = {PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy},
  journal = {Maturitas},
  year = {2025},
  doi = {10.1016/j.maturitas.2025.108670}
}
Kostenlos starten →